Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9NPF0
UPID:
CD320_HUMAN
Alternative names:
8D6 antigen; FDC-signaling molecule 8D6; Transcobalamin receptor
Alternative UPACC:
Q9NPF0; B2RDS5; D6W668; F5H6D3; Q53HF7
Background:
CD320 antigen, also known as the transcobalamin receptor, plays a crucial role in cobalamin (vitamin B12) uptake, essential for cellular metabolism and DNA synthesis. Expressed on follicular dendritic cells, it mediates B cell interaction, promoting their differentiation and proliferation. This receptor's interaction with germinal center B cells is pivotal for memory B-cell and plasma cell development.
Therapeutic significance:
The protein's involvement in methylmalonic aciduria, a metabolic disorder characterized by abnormal cobalamin uptake, underscores its therapeutic potential. Understanding CD320's role could open doors to novel strategies for managing this condition.